Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update | Zendy

Dolores Shoback | Zendy; Clifford J. Rosen | Zendy; Dennis M. Black | Zendy; Angela M. Cheung | Zendy; M. Hassan Murad | Zendy; Richard Eastell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update

Author(s) -

Dolores Shoback,

Clifford J. Rosen,

Dennis M. Black,

Angela M. Cheung,

M. Hassan Murad,

Richard Eastell

Publication year - 2020

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/clinem/dgaa048

Subject(s) - medicine , guideline , osteoporosis , sclerostin , adverse effect , clinical trial , postmenopausal women , endocrine system , intensive care medicine , gynecology , hormone , pathology , wnt signaling pathway , biochemistry , chemistry , gene

The objective is to provide an update of the 2019 Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline for the pharmacological management of osteoporosis in postmenopausal women using romosozumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research